摘要
目的观察白介素-21(IL-21)和白介素-2(IL-2)联合诱导的人外周血淋巴细胞(PBMC)抗卵巢癌细胞OVCAR-3的作用。方法收集河南省人民医院2015年1月至2016年1月健康志愿者外周血,密度梯度离心法分离人PBMC,分别用IL-2、IL-21或IL-2联合IL-21联合诱导培养,观察外周血中淋巴细胞增殖、细胞表型,并检测诱导的淋巴细胞对卵巢癌细胞株的杀伤作用。结果 IL-21处理组的淋巴细胞浓度高于IL-2单独处理组,IL-21具有较强的CD3CD56细胞亚群诱导作用,但两者联合并不能增进其促增殖和诱导CD3CD56亚群的作用。IL-21和IL-2联合诱导的淋巴细胞对OVCAR-3抑制率和促凋亡率最好,优于单用IL-2或IL-21。结论 IL-21和IL-2联合能增加外周血淋巴细胞杀伤卵巢癌细胞OVCAR-3的作用。
Objective To analyze the antitumor effect of PBMC induced by IL-21 combined with IL-2 on human ovarian cancer cell line OVCAR-3 in vitro. Methods PBMCs were isolated from human and treated with IL-2 and/or IL-21 in vitro. Proliferation and subtypes of lymphocytes induced by these cytokines were observed. Cytokine-activated lymphocytes were co-cultured with ovarian carcinoma cell line OVCAR-3. Tumor cell inhibition rate was detected by CCK-8 kit and apoptosis was observed by using FCM. Results Cell number in IL-21 group was more than that in IL-2 group,and similar for CD3 CD56 ratio. However combined treatment with IL-2 and IL-21 did improve these effects. Also lymphocytes induced by combined treatment had higher OVCAR-3 proliferation inhibition rate and apoptosis rate. Conclusion Combination of IL-21 and IL-2 could improve lymphocyte proliferation of PBMC and its antitumous effects to OVCAR-3.
出处
《医药论坛杂志》
2017年第9期1-4,共4页
Journal of Medical Forum
基金
河南省教育厅科技攻关计划(14B320034)
河南省科技厅科技攻关项目(142300410270)
